This week’s Neuroscience update highlights commercial launches, manufacturing partnerships, preclinical progress, portfolio expansion, health economics evidence, and updated care guidance across neurological disorders.
In Today’s Newsletter
Dive deeper
In Today’s Newsletter
💊 Akums launches lasmiditan dispersible tablets [1] [India • 18 Mar 2026]
https://www.expresspharma.in/akums-launches-first-of-its-kind-lasmiditan-dispersible-tablets-for-rapid-migraine-care/
Context: Akums Drugs & Pharmaceuticals said the DCGI-approved product is for acute migraine, with or without aura, in adults.
Key point: The company launched a dispersible lasmiditan formulation designed for easier administration during migraine attacks, especially when nausea or swallowing difficulty is present.
Implication: May influence prescriber choice and payer reviews pending full data.
🧬 Apertura and Viralgen align on TfR1 CapX manufacturing [2] [US/Spain • 17 Mar 2026]
https://www.prnewswire.com/news-releases/apertura-gene-therapy-and-viralgen-announce-strategic-collaboration-to-manufacture-tfr1-capx-a-next-generation-capsid-for-gene-therapies-designed-to-treat-central-nervous-system-diseases-302714462.html
Context: TfR1 CapX is described as an IV-dosed AAV capsid targeting human transferrin receptor 1 to cross the blood-brain barrier; evidence cited is preclinical.
Key point: Apertura Gene Therapy and Viralgen announced a strategic manufacturing collaboration so Apertura licensees can access TfR1 CapX within Viralgen’s AAV production platform.
Implication: Signals pipeline investment and modality expansion.
🧪 MIRA reports preclinical CNS tolerability signal for Mira-55 [3] [US • 23 Mar 2026]
https://www.accessnewswire.com/newsroom/en/healthcare-and-pharmaceutical/mira-pharmaceuticals-reports-mira-55-shows-no-thc-or-rimonabant-assoc-1150572
Context: MIRA Pharmaceuticals said the data came from validated behavioral assays in preclinical studies; oral doses and comparator details were reported by the company.
Key point: The company said Mira-55 did not show THC- or rimonabant-associated CNS side effects in the tested assays, while prior preclinical work had suggested analgesic activity.
Implication: May influence prescriber choice and payer reviews pending full data.
💼 Mankind Pharma acquires Rivotril in India [4] [India • 18 Mar 2026]
https://theindianpractitioner.com/mankind-pharma-acquires-rivotril-to-strengthen-cns-portfolio-in-india/
Context: Rivotril is the innovator brand of clonazepam; the report says Mankind gains rights to manufacture, market, and distribute it in India.
Key point: Mankind Pharma acquired Roche’s Rivotril brand for the Indian market to expand its CNS and specialty portfolio.
Implication: Signals pipeline investment and modality expansion.
📉 Plus Therapeutics highlights CNSide health economics analysis [5] [US • 19 Mar 2026]
https://www.manilatimes.net/2026/03/19/tmt-newswire/globenewswire/plus-therapeutics-to-present-new-analysis-at-ispor-showing-cnside-may-reduce-leptomeningeal-metastases-healthcare-costs-by-40/2303594
Context: The company said the analysis, for presentation at ISPOR 2026, used published literature, real-world data, and claims data for leptomeningeal metastases.
Key point: Plus Therapeutics said earlier diagnosis and therapeutic management using CNSide may lower LM-related healthcare costs, based on a health economics analysis.
Implication: Could inform practice and payer discussions; interpretation depends on study design and confounding control.
🧠 Anavex links new autophagy paper to blarcamesine rationale [6] [US • 20 Mar 2026]
https://www.manilatimes.net/2026/03/20/tmt-newswire/globenewswire/new-scientific-findings-highlight-hypothesis-of-autophagy-failure-as-a-precursor-of-amyloid-beta-and-tau-pathology-in-alzheimers-disease/2304374
Context: The release cites a peer-reviewed study proposing autophagy impairment as an upstream event in Alzheimer’s disease biology.
Key point: Anavex Life Sciences said the publication supports the mechanistic rationale for blarcamesine via SIGMAR1-mediated autophagy restoration; efficacy and safety were not established in this release.
Implication: Could inform practice and payer discussions; interpretation depends on study design and confounding control.
📘 Brain Trauma Foundation updates pTBI management guidance [7] [20 Mar 2026]
https://www.neurologyadvisor.com/features/penetrating-traumatic-brain-injury-guidelines-management/
Context: The second edition addresses imaging, vascular assessment, VTE prophylaxis, surgery, debridement, antibiotics, prognosis, and rehabilitation for penetrating traumatic brain injury.
Key point: The updated guidance recommends CT-first imaging, selective vascular follow-up, conservative debridement, selective antibiotic prophylaxis, and caution against early overly pessimistic prognostication.
Implication: Could inform practice and payer discussions; interpretation depends on study design and confounding control.
👶 Neurotech’s NTI164 gains visibility in pediatric neurology [8] [22 Mar 2026]
https://www.bitget.com/amp/news/detail/12560605291788
Context: The article cites Neurotech International’s orphan and rare pediatric disease designations for Rett syndrome and references Phase II/III proof-of-concept data in autism spectrum disorder.
Key point: A third-party market article presented NTI164 as a platform asset in pediatric neurology, tying its outlook to regulatory designations and earlier-stage clinical data.
Implication: Signals pipeline investment and modality expansion.
Why it Matters
- Migraine and CNS portfolios saw concrete commercial movement in India, via Akums’ lasmiditan formulation and Mankind’s Rivotril acquisition [1][4].
- CNS platform building remains active in gene therapy and pediatric neurology, with manufacturing readiness and regulatory positioning used as differentiators [2][8].
- Several items rely on preclinical, observational, or company-reported analyses, so interpretation should stay close to source language and evidence level [3][5][6].
- Health economics and guideline updates are shaping adoption conversations alongside efficacy, particularly in CNS diagnostics and acute neurotrauma care [5][7].
- Alzheimer’s disease messaging remains heavily mechanism-led, with autophagy framed as an upstream target rather than a validated clinical outcome in the supplied source [6].
🚀 Accelerate your success. Contact us now
📂 Explore our case studies. See examples of our work.
💡 Read our insights. Learn from our latest reports and analysis
🎬 Watch on YouTube. Subscribe and never miss a video.
🧰 See our full range of services. Discover how we can help you.
📚 View the full Neuroscience archive on our research hub page.
FAQ
What is TfR1 CapX from Apertura Gene Therapy?
TfR1 CapX is described by Apertura as an AAV capsid designed to bind human transferrin receptor 1 and cross the blood-brain barrier after IV dosing. The supplied release focuses on manufacturing readiness and preclinical positioning, not clinical outcomes [2].
What changed with the Brain Trauma Foundation’s pTBI guidance?
The updated guidance emphasizes CT as primary imaging, selective vascular imaging, conservative debridement, selective antibiotics, and caution against overly aggressive or prematurely nihilistic management decisions in penetrating TBI [7].
What did MIRA actually report for Mira-55?
MIRA reported preclinical behavioral data showing no THC- or rimonabant-associated CNS side effects in tested assays. The source also links this to prior preclinical analgesia work and planned IND-enabling steps for inflammatory pain [3].
What is the significance of Mankind Pharma acquiring Rivotril in India?
The deal adds an established clonazepam brand to Mankind’s CNS portfolio in India and gives it exclusive local manufacturing, marketing, and distribution rights, according to the supplied article [4].
Does the Anavex item show blarcamesine works in Alzheimer’s disease?
No. The supplied release connects a new mechanistic paper on autophagy failure to blarcamesine’s proposed SIGMAR1-mediated mechanism. It does not establish new clinical efficacy or safety in this item [6].
What is CNSide meant to do in leptomeningeal metastases?
Plus Therapeutics describes CNSide as a CSF assay intended to detect and monitor tumor cells in leptomeningeal metastases. The supplied item centers on a cost-of-care analysis suggesting earlier diagnosis and management could reduce healthcare costs [5].
Entities / Keywords
Akums Drugs & Pharmaceuticals, Lasmiditan, dispersible tablets, migraine, ditan, 5-HT1F agonist
Apertura Gene Therapy, Viralgen, TfR1 CapX, AAV capsid, rAAV, blood-brain barrier, CNS gene therapy
MIRA Pharmaceuticals, Mira-55, cannabinoid analog, CB1, CB2, inflammatory pain, IND
Mankind Pharma, Roche, Rivotril, clonazepam, CNS portfolio, India
Plus Therapeutics, CNSide, leptomeningeal metastases, LM, cerebrospinal fluid assay, ISPOR, health economics
Anavex Life Sciences, blarcamesine, SIGMAR1, autophagy, amyloid beta, tau, Alzheimer’s disease
Brain Trauma Foundation, penetrating traumatic brain injury, pTBI, CT angiography, debridement, antibiotic prophylaxis
Neurotech International, NTI164, Rett syndrome, autism spectrum disorder, orphan drug designation, rare pediatric disease designation
References
- https://www.expresspharma.in/akums-launches-first-of-its-kind-lasmiditan-dispersible-tablets-for-rapid-migraine-care/
- https://www.prnewswire.com/news-releases/apertura-gene-therapy-and-viralgen-announce-strategic-collaboration-to-manufacture-tfr1-capx-a-next-generation-capsid-for-gene-therapies-designed-to-treat-central-nervous-system-diseases-302714462.html
- https://www.accessnewswire.com/newsroom/en/healthcare-and-pharmaceutical/mira-pharmaceuticals-reports-mira-55-shows-no-thc-or-rimonabant-assoc-1150572
- https://theindianpractitioner.com/mankind-pharma-acquires-rivotril-to-strengthen-cns-portfolio-in-india/
- https://www.manilatimes.net/2026/03/19/tmt-newswire/globenewswire/plus-therapeutics-to-present-new-analysis-at-ispor-showing-cnside-may-reduce-leptomeningeal-metastases-healthcare-costs-by-40/2303594
- https://www.manilatimes.net/2026/03/20/tmt-newswire/globenewswire/new-scientific-findings-highlight-hypothesis-of-autophagy-failure-as-a-precursor-of-amyloid-beta-and-tau-pathology-in-alzheimers-disease/2304374
- https://www.neurologyadvisor.com/features/penetrating-traumatic-brain-injury-guidelines-management/
- https://www.bitget.com/amp/news/detail/12560605291788